Scientists recommend wider use of clot-busting stroke drug

09/25/2008 | Wall Street Journal, The

A stroke drug from Genentech called tissue plasminogen activator, marketed as Activase in the U.S., can be administered 4 1/2 hours after the onset of stroke symptoms -- past the three-hour limit recommended by the FDA -- a study concluded. Researchers found that 52% of patients who received TPA more than three hours after suffering a stroke survived with little impairment based on the Rankin scale while the rate for those who got placebo was 45%. The study was conducted in Europe by Boehringer Ingelheim, Genentech's business partner.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX